Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1

Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1
复制标题

DOI:
10.1086/503778
复制
发表时间:
2006-06-01
影响因子:
6.4
通讯作者:
Lallemant, M
Lallemant, M
中科院分区:
医学2区
文献类型:
--
作者:
Barin, F;Jourdain, G;Lallemant, M

文献摘要

被引文献

相似文献

我们分析了人类免疫缺陷病毒1型母婴传播(MTCT)与母体中和抗体的相关性,以验证保护性抗体是那些具有广泛中和活性的抗体的假设。我们的研究样本包括90名泰国妇女,她们知道艾滋病毒-1传播的时间(子宫内或产中)。统计分析包括控制血浆病毒载量和齐多夫定预防持续时间的条件Logistic回归模型。同一分支异源毒株的中和抗体效价越高,HIV-1的MTCT率就越低。更具体地说,MBA(CRF01_AE)毒株的高水平中和抗体与HIV-1在分娩期间的低传播有关。这表明,这种异源中和抗体可能参与了围产期晚期HIV传播的自然预防。这些数据与使用某些抗体可能有助于通过被动免疫预防来防止围产期艾滋病毒传播的假设一致。此外,对与HIV-1母婴传播相关的体液因素的研究可能会确定保护的相关因素,这应该有助于设计有效的艾滋病毒/获得性免疫缺陷综合征疫苗。
We analyzed the association between mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1) and maternal neutralizing antibodies to heterologous primary isolates of various HIV-1 clades, to test the hypothesis that protective antibodies are those with broad neutralizing activity. Our study sample included 90 Thai women for whom the timing of HIV-1 transmission ( in utero or intrapartum) was known. The statistical analysis included a conditional logistic-regression model to control for both plasma viral load and duration of zidovudine prophylaxis. The higher the titer of neutralizing antibodies to a heterologous strain of the same clade, the lower the rate of MTCT of HIV-1. More specifically, high levels of neutralizing antibodies to the MBA (CRF01_AE) strain were associated with low intrapartum transmission of HIV-1. This suggested that such heterologous neutralizing antibodies may be involved in the natural prevention of late perinatal HIV transmission. These data are consistent with the hypothesis that the use of some antibodies might help to prevent perinatal HIV transmission, through passive immunoprophylaxis. Moreover, the study of humoral factors associated with MTCT of HIV-1 may identify correlates of protection that should help in the design of efficient HIV/acquired immunodeficiency syndrome vaccines.